A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations
The purpose of this study is to evaluate the efficacy and safety of apatinib plus EGFR-TKI as first line treatment in patients with non-squamous NSCLC harboring EGFR mutation.
NSCLC
DRUG: Apatinib
Progression free survival, Baseline to measured date of progression or death from any cause, evaluated in two years since the treatment began
Objective response rate, Baseline to measured stable disease, tumor assessment every 8 weeks，up to two years|Disease control rate (DCR), Baseline to measured progressive disease, tumor assessment every 8 weeks，up to two years|Overall survival (OS), Baseline to measured date of death from any cause, the first day of treatment to death or last survival confirm date，up to two years|Adverse events, throughout study, evaluated in the two years since the treatment began according to the Common Terminology Criteria for Adverse Events Version 4.0
The purpose of this study is to evaluate the efficacy and safety of apatinib plus EGFR-TKI as first line treatment in patients with non-squamous NSCLC harboring EGFR mutation.